A Selective PPARγ Modulator Reduces Hepatic Fibrosis.

Area of Science:

• Hepatology
• Pharmacology
• Fibrosis Research

Background:

• Hepatic fibrosis, driven by chronic liver injury, leads to severe liver damage, including cirrhosis and cancer.
• Thiazolidinediones target peroxisome proliferator-activated receptor γ (PPARγ) and show antifibrotic effects but have limitations.
• Established fibrosis treatment remains challenging due to drug side effects and limited efficacy.

Purpose of the Study:

• To evaluate the efficacy of SR1664, a selective PPARγ modulator, in established hepatic fibrosis.
• To assess SR1664's impact on collagen deposition and hepatic stellate cell activation.
• To determine if SR1664 causes weight gain or adiposity.

Main Methods:

• Utilized a carbon tetrachloride-induced mouse model of established hepatic fibrosis.
• Administered SR1664 and monitored collagen content and hepatic stellate cell activation.
• Assessed changes in body weight and adiposity.

Main Results:

• SR1664 significantly reduced total and type 1 collagen in fibrotic livers.
• The drug decreased the abundance of activated hepatic stellate cells.
• SR1664 treatment did not increase body weight or adiposity.

Conclusions:

• Selective PPARγ modulation with SR1664 is effective against established hepatic fibrosis.
• SR1664 ameliorates the profibrotic phenotype of hepatic stellate cells.
• SR1664 represents a potential novel therapeutic strategy for liver fibrosis.